The global problem of antifungal resistance: prevalence, mechanisms, and management
- PMID: 28774698
- DOI: 10.1016/S1473-3099(17)30316-X
The global problem of antifungal resistance: prevalence, mechanisms, and management
Abstract
All serious fungal infections need appropriate antifungal therapy for successful patient outcome. Only a few classes of antifungal drugs are available, so the emergence of resistance to single drug classes and now multidrug resistance greatly hampers patient management. Azole resistance among Candida and Aspergillus species is one of the greatest challenges to clinical success, followed by echinocandin and multidrug resistance among some Candida species, especially Candida glabrata. The spread of agriculturally derived azole-resistant Aspergillus fumigatus and emerging threats such as multidrug resistant Candida auris are also alarming. The molecular mechanisms that cause drug resistance are naturally occurring in less susceptible species and are acquired in strains of susceptible organisms. Drug resistance mechanisms include altered drug-target interactions, reduced cellular drug concentrations mediated by drug efflux transporters, and permeability barriers associated with biofilms. Although C auris is inherently multidrug resistant, other strains typically develop resistance through stepwise selection of multiple drug-resistance mechanisms. Cellular stress induced by drug treatment promotes adaptation, which contributes to breakthrough resistance. Drug exposure also drives the emergence of resistance. An effective antifungal stewardship programme is essential to control drug resistance, and should incorporate rapid fungal diagnostics, therapeutic drug monitoring, and clinical intervention teams. The development of better diagnostic tools and strategies that allow targeted use of antifungals is essential to preserve drug effectiveness.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.Dan Med J. 2016 Oct;63(10):B5288. Dan Med J. 2016. PMID: 27697142 Review.
-
Antifungal drug resistance in pathogenic fungi.Med Mycol. 1998;36 Suppl 1:119-28. Med Mycol. 1998. PMID: 9988500 Review.
-
Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).Diagn Microbiol Infect Dis. 2016 Jun;85(2):200-4. doi: 10.1016/j.diagmicrobio.2016.02.009. Epub 2016 Feb 9. Diagn Microbiol Infect Dis. 2016. PMID: 27061369
-
New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans Candida Species.Curr Top Med Chem. 2019;19(28):2527-2553. doi: 10.2174/1568026619666191025152412. Curr Top Med Chem. 2019. PMID: 31654512 Review.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
Cited by
-
Inhibitory effect of magnetic iron-oxide nanoparticles on the pattern of expression of lanosterol 14α-demethylase (ERG11) in fluconazole-resistant colonising isolate of Candida albicans.IET Nanobiotechnol. 2020 Jul;14(5):375-381. doi: 10.1049/iet-nbt.2019.0354. IET Nanobiotechnol. 2020. PMID: 32691739 Free PMC article.
-
Structural and functional analysis of EntV reveals a 12 amino acid fragment protective against fungal infections.Nat Commun. 2022 Oct 13;13(1):6047. doi: 10.1038/s41467-022-33613-1. Nat Commun. 2022. PMID: 36229448 Free PMC article.
-
Novel Insights into the Antimicrobial and Antibiofilm Activity of Pyrroloquinoline Quinone (PQQ); In Vitro, In Silico, and Shotgun Proteomic Studies.Biomolecules. 2024 Aug 16;14(8):1018. doi: 10.3390/biom14081018. Biomolecules. 2024. PMID: 39199405 Free PMC article.
-
Targeting dermatophyte Cdc42 and Rac GTPase signaling to hinder hyphal elongation and virulence.iScience. 2024 May 28;27(6):110139. doi: 10.1016/j.isci.2024.110139. eCollection 2024 Jun 21. iScience. 2024. PMID: 38952678 Free PMC article.
-
Ecotoxicity and Mutagenicity Assessment of Novel Antifungal Agents VT-1161 and T-2307.Molecules. 2024 Oct 7;29(19):4739. doi: 10.3390/molecules29194739. Molecules. 2024. PMID: 39407667 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical